SMC
RVMD icon

Smith, Moore & Co’s Revolution Medicines RVMD Stock Holding History

Smith, Moore & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
7,000
+1,000
+17% +$146K 0.09% 192
2026
Q1 		$584K Hold
6,000
– – 0.04% 301
2025
Q4 		$478K Hold
6,000
– – 0.04% 326
2025
Q3 		$280K Buy
+6,000
New +$235K 0.02% 423

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Smith, Moore & Co's RVMD Position: Q2 2026 in Review

Smith, Moore & Co increased its Revolution Medicines (RVMD) stake by 17% in Q2 2026, buying an estimated $146K and bringing the position to 7,000 shares worth $1.31M. The position accounts for 0.09% of the portfolio, ranked #192.

Smith, Moore & Co first reported a position in RVMD in Q3 2025 and has held it in 4 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Smith, Moore & Co held 7,000 shares of Revolution Medicines worth $1.31M as of Q2 2026.
  • Smith, Moore & Co bought 1,000 Revolution Medicines shares in Q2 2026, an estimated $146K.
  • Revolution Medicines made up 0.09% of Smith, Moore & Co's portfolio in Q2 2026, its #192 holding.
  • Smith, Moore & Co first reported a position in Revolution Medicines in Q3 2025 and has held it in 4 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Smith, Moore & Co's 13F filing for Q2 2026, filed 12 Aug 2026.